

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Pharmacokinetics of florfenicol in serum and seminal plasma in beef bulls

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Romano, J.E., Bardhi, A., Pagliuca, G., Villadóniga, G.B., Barbarossa, A. (2024). Pharmacokinetics of florfenicol in serum and seminal plasma in beef bulls. *THERIOGENOLOGY*, 218, 276-281 [10.1016/j.theriogenology.2024.01.012].

Availability:

This version is available at: <https://hdl.handle.net/11585/1001044> since: 2025-01-10

Published:

DOI: <http://doi.org/10.1016/j.theriogenology.2024.01.012>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

1 **Pharmacokinetics of florfenicol in serum and seminal plasma in beef bulls**

2 Juan E. Romano^a, Anisa Bardhi^b, Giampiero Pagliuca^{bc}, Graciela B. Villadóniga^d, Andrea
3 Barbarossa^{bc}

4

5 ^a Cooperative of Agriculture and Research Center, College of Agriculture, Food and Natural
6 Resources, Prairie View A&M University, Prairie View, TX, 77446, USA

7 ^b Department of Veterinary Medical Sciences, University of Bologna, 40064, Ozzano dell'Emilia,
8 Bologna, Italy

9 ^c Health Sciences and Technologies-Interdepartmental Center for Industrial Research (CIRI-SDV),
10 University of Bologna, 40064, Ozzano dell'Emilia, Bologna, Italy

11 ^d St Joseph Regional Health Center, Pediatric Services, Bryan, TX, 77802, USA

12

13 **Abstract**

14 The objectives of this study were to compare the serum and seminal plasma pharmacokinetic profiles of
15 florfenicol (FLO) and florfenicol amine (FLA) after the administration of FLO either by IM or SC routes in
16 beef bulls. Four clinically healthy Hereford bulls underwent a comprehensive physical exam, including
17 breeding soundness examination, CBC, and chemistry profile panel. Bulls were healthy and classified
18 satisfactory potential breeders. In one group (n = 2), a single dose of FLO was administered SC in the middle
19 of the neck at a dose of 40 mg/kg of body weight. In the second group (n = 2), a single dose was administered
20 IM in the muscles of the neck at a dose of 20 mg/kg. Concentrations of FLO and FLA in serum and seminal
21 plasma were determined by ultra-high-performance liquid chromatography coupled to tandem mass
22 spectrometry (UHPLC-MS/MS). Blood and semen samples were collected before the administration of FLO
23 and at 12, 24, 36, 48, 72, 96, 120, 144, and 168 h after injection. The blood was collected from the coccygeal
24 vessels, and semen was collected by electroejaculation. All samples were immediately refrigerated, processed
25 within the first hour after collection, and finally stored at -80 °C. The mean level of total FLO in serum was
26 higher when administered by the SC route (1,415.5 ng/mL) than by the IM route (752.4 ng/mL; P = 0.001).
27 Differences were observed between the percentage of FLA in serum (1.8%; ranging from 1.3 to 2.9) and in
28 seminal plasma (27.5%; ranging from 15.9 to 34.2; P = 0.0001). The mean level (\pm SD) of FLA was higher in
29 seminal plasma compared to serum (467 ± 466 ng/mL and 18 ± 16 ng/mL, respectively; P = 0.001). The mean
30 level of total FLO in seminal plasma was 1,454.8 ng/mL for the SC route and 1,872.9 ng/mL for the IM route
31 without differences between the two routes (P = 0.51). Differences in the mean level of total FLO between
32 serum and seminal plasma were detected ($1,187 \pm 2,069$ ng/mL and $1,748 \pm 1,906$ ng/mL, respectively; P =
33 0.04). From the present investigation, it was concluded that FLO is a suitable antibiotic based on its
34 pharmacokinetic attributes and may be employed for the treatment of bull genital infections when its use is
35 indicated. To study the pharmacokinetics of FLO in seminal plasma, the analysis of FLA should be
36 incorporated.

37 **Keywords**

38 Bulls, Florfenicol, Florfenicol amine, Pharmacokinetics, Serum, Semen

39

40 **1. Introduction**

41 In bulls, the use of antibiotics is essential in various reproductive clinical conditions [[1], [2], [3]]. One of the
42 most common reproductive diseases in young and old bulls is the vesicular adenitis syndrome [3,4], and its
43 treatment often involves the use of local or systemic antibiotics [3,5]. In bulls, a variety of microorganisms
44 have been isolated from cases of vesicular adenitis syndrome including *Actinobacillus actinoides*, *Aeromonas*
45 *hydrophila*, *Brucella abortus*, *Chlamydomphila psittaci*, *Corynebacterium renale*, *Corynebacterium*
46 *pseudotuberculosis*, *Escherichia coli*, *Histophilus somni*, *Mycobacterium tuberculosis*, *Mycobacterium*
47 *paratuberculosis*, *Mycoplasmas*, *Proteus mirabilis*, *Streptococcus*, *Staphylococcus*, *Ureaplasmas*, *Trueperella*
48 *pyogenes*, and *Tritrichomonas foetus* [3]. In bulls the most frequent microorganism isolated is *Trueperella*
49 *pyogenes* [3,5]. However, most of the studies the selection of antibiotics for this last condition and other genital

50 infections (e.g. epididymitis) was based on personal experience, anecdotal evidence, extrapolation from other
51 species, and few were based on microbiological culture with identification and sensitivity test to the antibiotics
52 [3,5]. To ensure the appropriate choice of antibiotics, it is crucial to rely on microbiological culture, isolation,
53 identification, and sensitivity tests [3,5,6]. Administering the chosen antibiotic at the precise dose, route, and
54 frequency for an appropriate duration (antibiotic stewardship) is essential [7]. Careful and responsible use of
55 antibiotics is critical in minimizing the risk of microbial resistance. Recent research has reported new
56 information about two families of antibiotics found in bull's seminal plasma: macrolides and tetracycline [8,9].
57 This new knowledge is essential not only for designing effective treatment regimens but also for avoiding the
58 unnecessary use of antibiotics and preventing the development of antibiotic-resistant microorganisms. To
59 minimize medication errors and potential harm, following the “five rights” is proposed—ensuring the right
60 patient, the right drug, the right dose, the right route, and administering the treatment for the appropriate
61 duration [10]. Adhering to these principles can significantly improve treatment outcomes and patient well-
62 being.

63 Florfenicol exhibits a broad spectrum of antibacterial activity that includes all microorganisms sensitive to
64 chloramphenicol that comprised gram-negative bacilli, gram-positive cocci, several anaerobes, such as
65 *Bacteroides fragilis*, *Rickettsia* and *Chlamydia* spp., among other atypical microorganisms such as *Ureaplasma*
66 and *Mycoplasma* [[11], [12], [13], [14]]. It belongs to the family of antibiotics known as amphenicols, in which
67 mode of action is by inhibiting microbial protein synthesis through binding to the 50S subunit of the 70S
68 ribosome, thereby impairing peptidyl transferase activity and preventing peptide elongation. The typical effect
69 is bacteriostatic, but high concentrations can exhibit bactericidal properties against certain microorganisms.
70 Thiamphenicol and FLO, while structurally related to chloramphenicol, have modifications that enhance their
71 efficacy, reduce toxicity, and, in the case of FLO, decrease bacterial resistance by containing fluorine molecules
72 [11,12]. Florfenicol is considered a time-dependent antibiotic, although some information suggests that it may
73 also exhibit concentration-dependent or codependent behavior [[11], [12], [13], [14]]. It possesses
74 characteristics such as high bioavailability, lipophilicity, and adequate tissue penetration, enabling it to achieve
75 high levels within cells and cross certain anatomical barriers, making it effective against intracellular pathogens
76 [11,[13], [14], [15]]. Importantly, FLO is not susceptible to the actions of acetyltransferase, an enzyme used
77 by bacteria to develop resistance to chloramphenicol and thiamphenicol [16,17]. Florfenicol amine is the major
78 metabolite of degradation of FLO by acid-catalyzed hydrolysis. Florfenicol amine has not antibiotic activity
79 but is an important standard for monitoring animal and environmental residues of FLO [18].

80 The uses of FLO in veterinary medicine include the prevention and treatment of bovine respiratory disease
81 (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni*. It is also
82 employed for the treatment of bovine interdigital phlegmon associated with *Fusobacterium necrophorum* and
83 *Bacteroides melaninogenicus* [11,12]. In addition, FLO has demonstrated efficacy in treating calves with either
84 naturally occurring or experimentally induced keratoconjunctivitis [18,19], and its presence has been detected
85 in synovial fluid after regional intravenous perfusion [20] and parenteral administration [21].

86 To the best of our knowledge, the pharmacokinetics of FLO have not been investigated in either bulls or semen.
87 Given its known features mentioned above, this antibiotic presents an intriguing opportunity for examination
88 of its presence in semen. In addition, FLO was the most effective antibiotic against *Trueperella pyogenes*, the
89 most common pathogen of vesicular adenitis, with more than 95% of in vitro susceptibility of 144 isolates
90 [22]. Moreover, having a long-acting antibiotic available would reduce the frequency of administration and
91 animal handling, thereby minimizing animal stress and improving compliance. Investigating the
92 pharmacokinetic parameters of FLO at two doses, 20 mg/kg, or 40 mg/kg body weight, not only adds new
93 knowledge but also has practical significance. Bulls are large animals, requiring high-volume doses. It is
94 recommended to administer no more than 10 mL per injection site with at least a 10 cm space between
95 administration sites [23]. Therefore, dispensing FLO in mature bulls would necessitate multiple application
96 sites.

97 The objectives of this study were to compare the serum and seminal plasma pharmacokinetic profile of FLO
98 and its major active metabolite FLA after administration of FLO either by IM or SC routes in beef bulls.

99 **2. Material and methods**

100 2.1. Animals

101 Eight Hereford bulls were selected for the study based on their excellent temperament and healthy appearance.
102 Each bull underwent a comprehensive physical examination, including a breeding soundness examination
103 following the guidelines provided by the Society for Theriogenology [24]. Out of these eight bulls, four were
104 randomly chosen for the investigation. Additionally, blood samples were collected from the coccygeal vessels
105 and analyzed for CBC and chemistry profile to rule out any subclinical liver or kidney disease. The bulls were
106 healthy, and the CBC, as well as the chemical profile, showed that liver and kidney functions were normal.
107 Therefore, no potential interference of these organs that could have affected the pharmacokinetic parameters
108 of these bulls was detected. The age of the bulls was 22.3 ± 5.6 mo (range: 17.0–28.0). The weight was $366 \pm$
109 64 kg (307–455). The body condition score was 6.0 ± 0.4 (5.5–6.5) [25]. The bulls were kept together in a
110 common pasture and had access to free choice coastal hay and water ad libitum. Additionally, each bull
111 received 2.0 kg of concentrate cubes once a day, containing 14% crude protein, and had access to mineral salts.

112 2.2. Experimental design

113 The bulls used had not received any FLO administration. In one group ($n = 2$), a single dose of FLO was
114 administered SC route in the neck at a dose of 40 mg/kg of body weight (Nuflor, Intervet/Merck Animal Health
115 NJ, 07065). In the second group ($n = 2$), it was administered IM route in the muscles of the neck at a dose of
116 20 mg/kg of body weight. If the dose was greater than 10 mL, additional administration sites located within
117 10 cm of the original site were used. After injection, the sites were massaged vigorously to enhance the
118 distribution of the drug solution into the tissues.

119 The order of sample collection was blood and semen, collected at 0, 12, 24, 36, 48, 72, 96, 120, 144, and 168
120 h after FLO administration. Blood was collected from the coccygeal vessels using vacuum tubes without
121 additives and permitted to clot. Semen was collected from each bull by electroejaculation by using an electro-
122 ejaculator in automatic mode; the same set-up was used for all the bulls (Pulsator V, Lane Manufacturing,
123 Denver, CO, USA) using a two-electrode rectal probe of 60 mm diameter, as previously reported [26]. All the
124 bull's behavior responses during and after electroejaculation were monitored following previous criteria
125 already stated [26]. All the samples were immediately refrigerated, then centrifuged at 1,300 g for 30 min,
126 processed within the first hour, and stored at -80 °C. The procedures used in this investigation were performed
127 according to the standards for the “Use of Animals in Research and Education” by the World Organization for
128 Animal Health [27].

129 2.3. Florfenicol and florfenicol amine analysis

130 Florfenicol and florfenicol amine were measured in serum and seminal plasma samples using ultra-high-
131 performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS), as previously
132 described [28]. Before the experiment, the analytical method was validated following the
133 EMA/CHMP/ICH/172948/2019 guidelines [29]. The concentration ranges were appropriate for the levels
134 observed in actual samples: for FLO, it was 0.05–10 $\mu\text{g/mL}$ in both serum and seminal plasma, and for
135 florfenicol amine, it was 0.002–0.2 $\mu\text{g/mL}$ in serum and 0.005–1 $\mu\text{g/mL}$ in seminal plasma. The acquisition of
136 two specific MS/MS transitions for each analyte and the use of the deuterated internal standard FLO-d3
137 ensured reliable quantification of the compounds of interest.

138 2.4. Pharmacokinetic parameters

139 Noncompartmental analysis was utilized to estimate the pharmacokinetic parameters in serum and seminal
140 plasma for each individual animal. The standard software PK-Solver add-in for Excel [30] was employed to
141 estimate these pharmacokinetic parameters. The following variables were calculated for both serum and
142 seminal plasma of each animal: time of peak drug concentration (T_{max}); peak drug concentration (C_{max});
143 apparent elimination half-life ($t_{1/2}$), calculated as $\ln(2)/\lambda_z$, where λ_z represents the first-order rate constant
144 associated with the terminal portion of the time-concentration curve, estimated by linear regression of time
145 versus log concentration; area under the time-concentration curve from time zero to the last observed
146 concentration ($\text{AUC}_{0\text{-last}}$), calculated using the linear trapezoidal rule; area under the time-concentration curve
147 from time zero extrapolated to infinity ($\text{AUC}_{0\text{-inf}}$), calculated by adding the last observed concentration divided

148 by λ_z to the (AUC_{0-last}); area under the moment curve from time zero to last observed concentration ($AUMC_{0-$
149 $_{last}$); area under the moment curve from time zero extrapolated to infinity ($AUMC_{0-inf}$); mean resident time
150 estimated using time zero to last observed concentrations (MRT_{0-last} , calculated as $AUMC_{0-last}/AUC_{0-last}$); and
151 mean residence time estimated using time zero to infinity (MRT_{0-inf} , calculated as $AUMC_{0-inf}/AUC_{0-inf}$).2.5.
152 Statistical analysis

153 2.5. Statistical analysis

154 Statistical software [31] was utilized to calculate parameters such as the mean, standard deviation, and range.
155 The Student's T-test was employed for independent and paired samples. Furthermore, analysis of variance for
156 repeated samples using the General Linear Model was applied. Additionally, the software program PK-Solver,
157 as mentioned earlier [30], was used for pharmacokinetic parameter calculations. An alpha error of 5% was
158 adopted to accept the alternative hypothesis.

159 3. Results

160 The administration of FLO in both routes was well tolerated by all bulls throughout the study period, with mild
161 swelling and tenderness during the first two days, which disappeared by the end of the study. All the behavioral
162 responses during electroejaculation were moderate, mild, or light [26]. No changes in appetite, behavior,
163 urination, or feces consistency were noticed. Interestingly, the two routes of administration presented
164 differences in the pharmacokinetic parameters of FLO in serum but not in seminal plasma.

165 The mean level of total FLO in serum was higher with the SC route (1,415.5 ng/mL) compared to the IM route
166 (752.4 ng/mL; $P = 0.001$; Fig. 1). Differences were also observed in the mean levels of FLO and FLA between
167 SC (666 versus 10.98 ng/mL; $P = 0.02$) and IM (252.86 versus 21.13 ng/mL; $P = 0.03$) routes of administration,
168 respectively.

169 In serum, the percentage of FLA was 1.98% (range 1.3–2.9) for the IM route and 1.69% (1.5–1.8) for the SC
170 route ($P = 0.38$). The mean level of total FLO in seminal plasma was 1,454.8 ng/mL for the SC route and
171 1,872.9 ng/mL for the IM route, with no significant differences between the two routes ($P = 0.51$; see Fig. 2).

172 The curves of total FLO (florfenicol + florfenicol amine) concentration (ng/mL) in seminal plasma through
173 the experimental period after single administration of FLO by IM (20 mg/kg) or SC (40 mg/kg) routes are
174 presented in Fig. 2. In seminal plasma, the percentage of FLA was 29.0 % (range 24.1–34.2%) for the IM route
175 and 25.9% (range 15.9 and 32.3%) for the SC route ($P = 0.52$). The mean level (\pm SD) of FLA was higher in
176 seminal plasma compared with serum (467 ± 466 and 18 ± 16 , respectively; $P = 0.001$). Differences in the
177 mean levels of total FLO between serum and seminal plasma were detected ($1,187 \pm 2,069$ ng/mL and
178 $1,748 \pm 1,906$ ng/mL, respectively; $P = 0.04$). Fig. 3 presents the concentration of total FLO (ng/mL) in serum
179 and seminal plasma throughout the investigation period.

180 Pharmacokinetics parameters calculated for non-compartmental analysis of serum and seminal plasma are
181 described in Table 1. The total FLO in seminal plasma concentrations presented a C_{max} of 7,084.20 ng/mL at
182 24 h by the SC route and a C_{max} of 5,330.5 ng/mL at 42 h for the IM route, without differences between both
183 routes ($P = 0.39$). No differences in the other seminal plasma pharmacokinetics parameters such as half-life,
184 AUC, AUMC, and MRT between SC and IM routes were detected.

185 4. Discussion

186 In previous reports, the administration of FLO by IM route (20 mg/kg) in six lactating Holstein cows resulted
187 in C_{max} in serum of 2.3 μ g/mL at 3 h [32]; a C_{max} of 2.7 μ g/mL at 4.4 h when injected by the IM route
188 (20 mg/kg) in five 12-month-old. Black Pied heifers [33]; a C_{max} in plasma of 2.98 μ g/mL at 12 h in six
189 lactating Holstein cows injected by the SC route (40 mg/kg) [34]; a C_{max} in serum of 3.07 μ g/mL (harmonic
190 mean) at 18.3 h detected in ten calves between 3 and 6 months of age injected by the IM route (20 mg/kg)
191 [35]; a C_{max} in plasma of 3.18 μ g/mL at 0.38 h in six male calves Holstein-Friesian injected by the IV route
192 (20 mg/kg) [13]; a C_{max} of 3.2 μ g/mL at 6.8 h in five 12-month-old Black Pied heifers injected by the SC route
193 (40 mg/kg) [33]; a C_{max} of 3.21 μ g/mL at 3.3 h in ten calves receiving by the IM route (20 mg/kg) [15]; a C_{max}
194 in plasma of 3.42 μ g/mL at 1.19 h in six 6-month-old castrated calves by the SC route (40 mg/k) [14]; a C_{max}

195 of 4.9 µg/mL 7.6 h in five mature cows by the SC route (40 mg/kg) [36]; a C_{max} of 5.4 µg/mL at 4 h after oral
196 administration to six male veal Holstein calves (11 mg/kg) [37]; a C_{max} in serum of 5.90 µg/mL at 0.63 h when
197 it was applied via IV route (2.2 mg/kg) in the dorsal common digital vein of six cows [20]; a C_{max} in serum of
198 9.41 µg/mL at 3.3 h in six Holstein calves between 1 and 8 weeks old when orally administered (22 mg/kg)
199 [38]. From all these studies, a wide variation in C_{max} and T_{max} was noticed. In the present study, the levels of
200 total FLO in serum were higher in the SC route than the IM route throughout the experimental period, with a
201 C_{max} of 2,830.2 ng/mL at 12 h for the IM route (20 mg/kg) and 3,668 ng/mL at 12 h when SC administered
202 (40 mg/kg). These findings agreed with some of the previous reports and with a recent study that compared
203 both routes in 12-month-old heifers [33]. In the present investigation, the values in serum of total FLO for both
204 routes were in consonance with those previous reports, allowing us to be confident that the outcomes in seminal
205 plasma were reliable.

206 The half-life of FLO in plasma was affected by the route of administration, with a half-life of 2–3 h after IV,
207 18 h after IM, and 27 h after SC administration [11]. In the present study, the outcomes agree with those
208 findings, showing that the IM route had a shorter half-life than the SC route in serum [33]. Interestingly, the
209 half-life of FLO in the seminal plasma presented no differences between routes.

210 The effectiveness of any antimicrobial is established by both its pharmacokinetics (PK) and
211 pharmacodynamics properties (PD) [39,40]. In veterinary medicine, three PK/PD indices are routinely used:
212 the ratio of the area under the curve of the free drug plasma concentration to the minimum inhibitory
213 concentration (MIC) (AUC/MIC), the peak antibiotic concentration to MIC ratio (C_{max}/MIC), and the time that
214 free plasma concentration exceeds the MIC over the dosing interval ($T > MIC$). Among these, the AUC higher
215 than MIC for a specific microorganism (AUC/MIC) is considered the primary
216 pharmacokinetic/pharmacodynamics forecaster for clinical effectiveness.

217 Therefore, prior to using FLO in bulls, it is important to understand its pharmacokinetics, particularly the
218 duration of time that the concentrations of this medicine are maintained above the MIC for targeted pathogens
219 throughout the treatment period. As shown in this study, FLO was present in both serum and seminal plasma
220 throughout the experimental period of seven days. Moreover, the levels of FLO in seminal plasma were higher
221 than in serum. This information will be critical in designing appropriate treatment protocols based on the levels
222 of FLO in seminal plasma at specific times after administration.

223 The use of FLO for the treatment of bovine respiratory disease was based on two schemes of administration:
224 a single SC injection at a dose of 40 mg/kg or two IM injections at a dose of 20 mg/kg with a two-day interval
225 [11,12]. In the present study, the pharmacokinetic values in serum for both routes of administration showed
226 that the level of FLO above 500 ng/mL was between 48 and 72 h for the IM route and between 120 and 144 h
227 for the SC route, in agreement with a recent investigation [33].

228 In a previous investigation, when oxytetracycline long-lasting was administered to Simmental bulls at
229 10 mg/kg or 20 mg/kg, differences between doses in the mean level of oxytetracycline in seminal plasma, as
230 well as C_{max} , AUC and AUMC, were detected [9]. However, in the present study, no differences in seminal
231 plasma were observed in the mean total FLO concentrations, as well as in all pharmacokinetics parameters
232 compared (C_{max} , T_{max} , $T_{1/2}$, AUC, AUMC, and MRT) between doses. This outcome was unexpected, especially
233 considering that the bulls injected by SC received a double dose of FLO compared to the IM route. The reasons
234 for this observation are unknown, but one probable reason could be that there was a threshold of transport of
235 FLO through the accessory sexual glands. Consequently, even though the levels were higher in serum for the
236 SC route, a level of saturation could have been reached for the male genital tract tissues. This finding has
237 multiple remarkable implications. On one side, the administration of FLO by IM was as effective as the SC
238 route in all pharmacokinetics parameters compared, resulting in a reduced volume of administration, decreased
239 treatment costs, and a significant reduction in the withdrawal time as well [11,12]. It is necessary to remark
240 that the use of FLO in bulls for reproductive diseases such as vesicular adenitis syndrome will be considered
241 in the USA as extra label use because no indication was specified in the label; therefore, it is necessary to
242 determine that the meat withdraw time will be longer than for those recommended in the label (28 days for
243 IM versus 38 days for SC routes) [11,12].

244 The administration of FLO by the IM route (20 mg/kg) in lactating Holstein cattle resulted in a serum C_{max} of
245 2.3 $\mu\text{g/mL}$ at 3 h and a C_{max} in milk of 1.6 $\mu\text{g/mL}$ at 10 h [32]. In a second study, the administration of FLO by
246 the SC route (40 mg/kg) in lactating cows also resulted in a C_{max} in plasma of 2.98 $\mu\text{g/mL}$ at 12 h and a C_{max}
247 in milk of 1.74 $\mu\text{g/mL}$ at 12 h [34]. From these studies, it was observed that C_{max} in milk was between 58 and
248 70% of the plasma or serum level. In pigs, the C_{max} of FLO in plasma after IM administration (15 mg/kg) was
249 3.58 $\mu\text{g/mL}$ at 1.64 h, and the C_{max} in synovial fluid was 2.73 $\mu\text{g/mL}$ at 3.4 h [41]. Therefore, the maximum
250 level in synovial fluid was 76% of the plasma level. When FLO was administered to beef cows by the SC route
251 (40 mg/kg), and synovial samples were collected from the metatarsophalangeal joint for 10 days, the C_{max} was
252 2.7 $\mu\text{g/mL}$, which was 50% of the estimated plasma C_{max} used from another study [21]. In interstitial fluid, it
253 was found that the FLO levels were below the plasma level [14]. FLO concentrations in the brain, cerebrospinal
254 fluid, and aqueous humor were one fourth to one-half of the serum level [14,37]. However, a further
255 independent study found that FLO presented a C_{max} higher (47%) in the cerebrospinal fluid compared to serum
256 levels [13]. Finally, in the use of a tissue cage model for calf pneumonia microorganisms, calves that received
257 40 mg/kg by the SC route resulted in a serum C_{max} of 5.91 $\mu\text{g/mL}$, which was higher than those of exudate
258 (3.39 $\mu\text{g/mL}$) and transudate (2.84 $\mu\text{g/mL}$) [42]. From all these previous studies, it was observed that FLO
259 levels in tissues were lower than those in plasma or serum, except for the lungs, where levels were more than
260 200% of serum levels [14,36]. In the present study, the persistence of levels ≥ 500 ng/mL of total FLO was
261 longer in seminal plasma (5 days) than in serum (3 days).

262 In the present study, the level of total FLO in seminal plasma was above serum levels during all the
263 experimental periods. Moreover, using serum levels of FLO as a source of information to establish a correct
264 treatment regimen for genital infections in bulls could be considered a misleading approach based on the
265 pharmacokinetic parameters of FLO from the present investigation. In two recent studies, using different
266 families of antibiotics such as macrolide (Tulathromycin) or tetracycline (Oxytetracycline), the concentrations
267 were higher and persisted longer compared with plasma levels [8,9]. Consequently, further investigation is
268 necessary to determine if the male genital tract has a special affinity for these different families of antibiotics
269 due to the high levels in seminal plasma compared with serum or plasma levels.

270 One remarkable aspect of the present investigation was the assessment of both FLO and FLA in serum and
271 seminal plasma. This methodology allowed us to observe that the FLA levels between both fluids were not
272 only different, being almost 2% in serum and around 27.5% for seminal plasma, but it also revealed differences
273 in the total level of FLO between both fluids. Without this new approach of analysis for both products, these
274 differences in FLO levels between serum and seminal plasma would not have been possible to detect. More
275 investigation to determine the high levels of FLA in seminal plasma compared with serum is required. It seems
276 that the male genital tract maybe produced this metabolite or has the capacity to accumulate it.

277 In the present research, several weaknesses were identified, including a limited number of bulls, bulls of the
278 same age, a single breed, and the inclusion of only clinically healthy bulls. Additionally, wide variations in the
279 levels of FLO, as described in former experiments, were also noticed. Nevertheless, the evidence generated
280 could be considered a starting point not only for establishing a primary treatment regime for bulls that requires
281 the use of FLO but also for future studies on this topic. The effects of FLO on reproductive performance have
282 not been determined yet, therefore, precautions about its use on animals of breeding age are recommended.
283 Studies about FLO for the treatment of vesicular adenitis cases are necessary. Moreover, toxicity studies in
284 dogs, rats, and mice have been associated with testicular degeneration and atrophy. Further investigations are
285 necessary to enhance the current information on this matter.

286 Based on the present study, it has been concluded that FLO exhibits pharmacokinetic attributes that make it a
287 suitable antibiotic for the treatment of bull genital infections, provided its use is appropriately indicated by the
288 sensitivity of the microorganism isolated to FLO. To further study the pharmacokinetics of FLO in seminal
289 plasma, the analysis of FLA should be incorporated.

290 **Conflicts of interest**

291 All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality
292 of the research reported.

293 **Credit authorship contribution statement**

294 **Juan E. Romano:** Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology,
295 Supervision, Writing – original draft, Writing – review & editing. **Anisa Bardhi:** Analysis of samples by
296 UHPLC-MS/MS. Manuscript review. **Giampiero Pagliuca:** Analysis of samples by HP-LC. Manuscript
297 review. **Graciela B. Villadóniga:** Pharmacokinetic analysis. Writing and manuscript review. **Andrea**
298 **Barbarossa:** Analysis of samples by UHPLC-MS/MS. Manuscript review.

299

300 **Acknowledgments**


301 The authors express their gratitude to 3R Ranch Livestock Co., located in Somerville, Burleson County, Texas,
302 for granting permission to use their bulls in this research. Special thanks go to the ranch personnel for their
303 valuable assistance throughout the project. The funding for this project was provided by 3R Ranch Livestock
304 Co., the Cooperative Agriculture Research Center of the College of Agriculture and Human Sciences at Prairie
305 View A&M University, and the Department of Veterinary Medicine at the University of Bologna.

306 **References**

- 307 [1] Montes AJ, Wolfe DF, Welles EG, Tyler JW, Tepe E. Infertility associated with Eperythrozoon
308 wenyonii infection in a bull. *J Am Vet Med Assoc* 1994;204:261–3.
- 309 [2] Welles EG, Tyler JW, Wolfe DF, et al. Eperythrozoon infection in young bulls with scrotal and
310 hindlimb edema, a herd outbreak. *Theriogenology* 1995;43:557–67.
- 311 [3] Romano JE, Brinsko SP, Blanchard TL, Varner DD. Male reproductive disorders. In: Smith BP, Van
312 Metre D, Pusterla N, editors. *Large animal internal medicine*. sixth ed. Elsevier Inc; 2020. p. 1505–19.
- 313 [4] Ball L, Griner LA, Carroll EJ. The bovine seminal vesiculitis syndrome. *Am J Vet Res* 1964;25:291–
314 302.
- 315 [5] Martínez MF, Arteaga AA, Barth AD. Intraglandular injection of antibiotics for the treatment of
316 vesicular adenitis in bulls. *Anim Reprod Sci* 2008;104:201–11.
- 317 [6] Romano JE. New aseptic technique of semen collection for microbiological culture in bulls Proc 30th
318 world Buiatric Congress. Japan: Sapporo; 2018. p. 137–8.
- 319 [7] Srinivasan A. Antibiotic stewardship: why we must, how we can. *Cleve Clin J Med* 2017;84:673–9.
- 320 [8] Romano JE, Barbarossa A, Pagliuca P, Villado'niga G, Gazotti T, Mislei B, Zironi E,
321 Mari G. Pharmacokinetics of tulathromycin on plasma and semen of beef bulls. *Theriogenology* 2022;177:50–
322 5.
- 323 [9] Romano JE, Barbarossa A, Pagliuca P, Villado'niga G, Gazotti T, Mislei B, Zironi E, Mari G.
324 Pharmacokinetics of oxytetracycline long acting on plasma and semen of beef bulls. *Theriogenology*
325 2022;186:21–6.
- 326 [10] Dryden M, Johnson AP, Ashiru-Oredope D, Sharland M. Using antibiotics responsibly: right drug,
327 right time, right dose, right duration. *J Antimicrob Chemother* 2011;66:2441–3.
- 328 [11] Papich MG. *Papich handbook of veterinary drugs*. fifth ed. Elsevier Saunders Co.; 2020. p. 370–3.
- 329 [12] Nuflor. Merck animal Health. Intervet Inc. Giralda Fram, Madison NJ, 07940. Product Information
330 (Florfenicol). Approved by FDA under NADA #141–063.
- 331 [13] Craene BA de, Deprez P, D'Haese E, Nelis HJ, Van den Bossche W, Leenheer. Pharmacokinetics of
332 Florfenicol in cerebrospinal fluid and plasma of calves. *Antimicrob Agents Chemother* 1997;41:1991. –5.


- 333 [14] Foster DM, Martin LG, Papich MG. Comparison of active drug concentrations in the pulmonary
334 epithelial lining fluid and interstitial fluid of calves injected with enrofloxacin, florfenicol, ceftiofur, or
335 tulathromycin. *PLoS One* 2016;11(2): e0149100. <https://doi.org/10.1371/journal.pone.0149100>.
- 336 [15] Varma KJ, Sams RA, Lobell RD, Lockwood PW. Pharmacokinetics and efficacy of a new broad
337 spectrum antibiotic florfenicol in cattle. *Acta Vet Scand* 1991;87:102–4.
- 338 [16] Cannon M, Harford S, Davies J. A comparative study on the inhibitory actions of chloramphenicol,
339 thiamphenicol and some fluorinated derivatives. *Antimicrob. Chemotherapy* 1990;26:307–17.
- 340 [17] Paape MJ, Miller RH, Ziv G. Effects of florfenicol, chloramphenicol and thiamphenicol on
341 phagocytosis, chemiluminescence, and morphology of bovine polymorphonuclear neutrophil leukocytes. *J*
342 *Dairy Sci* 1990;73:1734–44.
- 343 [18] Angelos JA, Dueger EL, George W, Carrier TK, Mihalyi JE, Cosgrove SB, et al. Efficacy of florfenicol
344 for treatment of naturally occurring infectious bovine keratoconjunctivitis. *J Am Vet Med Assoc* 2000;216.
- 345 [19] Dueger EL, Angelos JA, Cosgrove S, Johnson J, George LW. Efficacy of florfenicol in the treatment
346 of experimentally induced infectious bovine keratoconjunctivitis. *Am J Vet Res* 1999;60:960–4.
- 347 [20] Gilliam JN, Streeter RN, Papich MG, Washburn KE, Payton ME. Pharmacokinetics of florfenicol in
348 serum and synovial fluid after regional intravenous perfusion in the distal portion of the hind limb of adult
349 cows. *Am J Vet Res* 2008;69:997–1004.
- 350 [21] Jones ML, Washburn KE, Fajt VR, Rice S, Coetzee JF. Synovial fluid pharmacokinetics of
351 tulathromycin, gamithromycin and florfenicol after a single subcutaneous dose in cattle. *BMC Vet Res*
352 2015;11:26.
- 353 [22] Ribeiro MG, Riseti RM, Bolan˜os CAD, Caffaro KA, de Moraes ACB, Lara GH, et al.
354 *Trueperella pyogenes* multispecies infections in domestic animals: a retrospective study of 144 cases (2002 to
355 2012). *Vet Q* 2015;35:82–7.
- 356 [23] Beef Quality Assurance – National manual – chapter 4. Herd Health management. Web access on April
357 14th, 2023.
- 358 [24] Koziol JH, Armstrong CL. Manual for breeding soundness examination of bulls. second ed. Society
359 for Theriogenology; 2018. p. 147.
- 360 [25] Richards MW, Spitzer JC, Warner MB. Effect of varying levels of postpartum nutrition and body
361 condition at calving on subsequent reproductive performance in beef cattle. *J Anim Sci* 1986;62:300–6.
- 362 [26] Romano JE, Mari G, Stradaoli G, Mislei B. Effect of fasting prior to electroejaculation on behavioral
363 responses and reproductive parameters in young Simmental bulls. *Theriogenology* 2021;173:19–22.
- 364 [27] Use of Animals in Research and Education. In: *Terrestrial animal Health code*. World Organization of
365 Animal Health; 2022. p. 1–12 [Chapter 7].8.
- 366 [28] Bardhi A, Romano JE, Pagliuca G, Caneschi A, Barbarossa A. Florfenicol and florfenicol amine
367 quantification in bull serum and seminal plasma by a single validated UHPLC-MS/MS method. *Vet Med Int*
368 2023:6692920.
- 369 [29] EMA - European Medicines Agency. ICH guideline M10 on bioanalytical method validation and study
370 sample analysis. 25 July 2022. EMA/CHMP/ICH/172948/ 2019, London, U.K.
- 371 [30] Zhang Y, Huo M, Zhou J, Xie S. PK-Solver: an add-in program for pharmacokinetic and
372 pharmacodynamic data analysis in Microsoft Excel. *Comput Methods Progr Biomed* 2010;99:306–14.
- 373 [31] Minitab 21. Minitab Inc. State College, PA, USA.

- 374 [32] Soback S, Pappé MJ, Filep R, Varma KJ. Florfenicol pharmacokinetics in lactating cows after
375 intravenous, intramuscular and intramammary administration. *J Vet Pharmacol Therapeut* 1995;18:413–7.
- 376 [33] Selimov R, Goncharova E, Koriakovtsev P, Gabidullina D, Karsakova J, Kozlov S, et al. Comparative
377 pharmacokinetics of florfenicol in heifers after intramuscular and subcutaneous administration. *J Vet*
378 *Pharmacol Therapeut* 2023;6:177–84.
- 379 [34] Kawalek JC, Howard KD, Jones Y, Scott MJ. Myer. Depletion of florfenicol in lactating dairy cows
380 after intramammary and subcutaneous administration. *J Vet Pharmacol Therapeut* 2016;39:602–11.
- 381 [35] Lobell RD, Varma KJ, Johnson JC, Sams RA, Gerken DF, Ashcraft SM. Pharmacokinetics of
382 florfenicol following intravenous and intramuscular doses to cattle. *J Vet Pharmacol Therapeut* 1994;17:253–
383 8.
- 384 [36] Lacroix MZ, Gayraud-Troy VV, Picard-Hagen N, Toutain PL. Comparative bioavailability between
385 two routes of administration of florfenicol and flunixin in cattle. *Rev Med Vet* 2011;162:321–4.
- 386 [37] Adams PE, Varma KJ, Powers TE, Lamendola JF. Tissue concentrations and pharmacokinetics of
387 florfenicol in male veal calves given repeated doses. *Am J Vet Res* 1987;48:1725–32.
- 388 [38] Varma KJ, Adams PE, Powers TE, Powers JD, Lamendola JF. Pharmacokinetics of florfenicol in veal
389 calves. *J Vet Pharmacol Therapeut* 1986;9:412–25.
- 390 [39] Toutain PL, Pelligand L, Lees P, Bousquet-M'elou A, Ferran AA, Turnidge JD. The
391 pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: recent advances
392 and critical appraisal. *J Vet Pharmacol Therapeut* 2021;44:172–200.
- 393 [40] Papich MG. Pharmacokinetic–pharmacodynamic (PK–PD) modeling and the rational selection of
394 dosage regimes for the prudent use of antimicrobial drugs. *Vet Microbiol* 2014;171:480–6.
- 395 [41] Somogyi Z, Mag P, Kova'cs D, Kerek A', Szabo' P, Makrai L, et al. Synovial and
396 systemic pharmacokinetics of florfenicol and PK/PD integration against *Streptococcus suis* in pigs.
397 *Pharmaceutics* 2022;14:109. <https://doi.org/10.3390/pharmaceutics14010109>.
- 398 [42] Rassouli A, Lees P, Sidhu P. Florfenicol pharmacokinetics in calves following a single subcutaneous
399 injection. *J Vet Res* 2011;66:95–101.




400

401 Fig. 1. Mean (+1 SD) total florfenicol (florfenicol + florfenicol amine) concentration (ng/mL) in serum after
 402 single administration either by IM or SC routes in four Hereford bulls.



403

404 Fig. 2. Mean (+ SD) seminal plasma of total florfenicol (florfenicol + florfenicol amine) concentration (ng/mL)
 405 after single administration of florfenicol either by IM (20 mg/kg) or SC (40 mg/kg) routes in four Hereford
 406 bulls.



407

408 Fig. 3. Mean (+ SD) serum and seminal plasma of total florfenicol (florfenicol + florfenicol amine)
 409 concentration (ng/mL) after single administration (SC and IM combined) in four Hereford bulls.

410 Table 1

411 Serum and seminal plasma pharmacokinetics parameters of total florfenicol (florfenicol + florfenicol amine)
 412 administered by IM route (20 mg/kg) and SC route (40 mg/kg) in beef bulls.

| Parameter | Unit | Serum | | Probability | Seminal Plasma | | Probability |
|--------------------------|----------------------|---------|---------|-------------|----------------|--------------|-------------|
| | | IM | SC | | IM | SC | |
| Lambda z (λ_z) | 1/h | 0.01733 | 0.01112 | P = 0.06 | 0.02137 | 0.02009 | P = 0.46 |
| T 1/2 | h | 40.7 | 62.7 | P = 0.04 | 38.3 | 38.1 | P = 0.49 |
| T max | h | 12.0 | 18.0 | P = 0.43 | 24.0 | 42.0 | P = 0.16 |
| C max | ng/mL | 2,830.2 | 3,668.3 | P = 0.04 | 7,084.2 | 5,330.5 | P = 0.39 |
| AUC _{0-last} | ng/mL*h | 1,421.1 | 1,840.1 | P = 0.06 | 200,595.3 | 293,844.9 | P = 0.34 |
| AUC _{0-inf} | ng/mL*h | 2,125.7 | 2,754.2 | P = 0.04 | 215,804.2 | 304,312.8 | P = 0.34 |
| AUMC _{0-last} | ng/ml*h ² | 1,773.4 | 2,297.2 | P = 0.001 | 7,915,593.6 | 15,417,021.6 | P = 0.26 |
| AUMC _{0-inf} | ng/mL*h ² | 1,949.5 | 2,525.7 | P = 0.004 | 11,579,231.9 | 17,757,147.6 | P = 0.30 |
| MRT _{0-last} | h | 37.8 | 55.4 | P = 0.03 | 45.8 | 51.1 | P = 0.40 |
| MRT _{0-inf} | h | 47.4 | 82.6 | P = 0.02 | 62.8 | 60.6 | P = 0.48 |

413 λ_z being the first order rate constant associated with the terminal portion of the time-concentration curve;
 414 T1/2: apparent elimination half-time calculated as $\ln(2)/\lambda_z$; Tmax: time of peak drug concentration; Cmax:
 415 peak of drug concentration; AUC_{0-last}: area under the time-concentration curve from time zero to the last
 416 observed concentration; AUC_{0-inf}: area under the time-concentration curve from time zero extrapolated to
 417 infinity; AUMC_{0-last}: area under the moment curve from time zero extrapolated to last observed
 418 concentration; AUMC_{0-inf}: area under the moment curve from time zero extrapolated to infinity; MRT₀₋
 419 last: Mean resident time calculated as AUMC_{0-last}/AUC_{0-last}; MRT_{0-inf}: Mean resident time calculated as
 420 AUMC_{0-inf}/AUC_{0-inf}. Mean pharmacokinetics parameters in plasma and seminal plasma calculated via
 421 noncompartmental analysis.